An investigation for investors in NASDAQ:ADRO shares was announced over potential securities laws violations by Aduro BioTech Inc and certain of its directors and officers.
Investors who purchased shares of Aduro BioTech Inc (NASDAQ:ADRO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether a series of statements by Aduro BioTech Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On May 16, 2016, Berkeley, CA based Aduro BioTech Inc announced that the Phase 2b ECLIPSE trial did not meet the primary endpoint of an improvement in overall survival for patients with pancreatic cancer who had failed at least two prior therapies in the metastatic setting. Shares of Aduro BioTech Inc (NASDAQ:ADRO) declined to as low as $7.26 per share on May 16, 2016.
On May 31, 2016, NASDAQ:ADRO shares closed at $12.29 per share.
Those who purchased NASDAQ:ADRO shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com